Headache is a very common problem presenting to primary care physicians and neurologists.
Most headaches are diagnosed based on the history & physical exam w/ no imaging or laboratory examination necessary.
Other types of headaches such as secondary headaches may require further evaluation & referral to a specialist.
After treatment with fremanezumab, a difficult-to-treat patient population with treatment-resistant episodic or chronic migraine saw sustained benefits across a broad range of measures, according to multiple analyses of the FOCUS study released during the AHS 2020 Virtual Meeting.
The CGRP* receptor blocker erenumab shows sustained efficacy in reducing migraine frequency over 2 years in a difficult-to-treat patient population with episodic migraine who had failed 2–4 prior preventive treatments, an interim analysis of the LIBERTY** open-label extension study shows.
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
The standard combination therapy against paediatric migraine—consisting of a combination of parenteral medications—appears to yield moderate pain relief, which persists up to 1 week after administration, a new study has found.
The phase III OPTIMUM (Oral Ponesimod Versus Teriflunomide In Relapsing Multiple Sclerosis) study shows that ponesimod is superior to teriflunomide in reducing annualized relapse rate (ARR), fatigue, MRI activity, and brain volume loss in relapsing multiple sclerosis (RMS).